PTEN inhibition enhances sensitivity of ovarian cancer cells to the poly (ADP-ribose) polymerase inhibitor by suppressing the MRE11-RAD50-NBN complex.

Lipeng QiuRuyan LiYue WangZiwen LuZhigang Tu Hanqing Liu

Published in: British journal of cancer (2024)

Collectively, this study highlights the potential of PTEN inhibitors in combination therapy with PARPis to create HRD for HRD-negative ovarian cancers.

Keyphrases

combination therapy
cell proliferation
pi k akt
signaling pathway
oxidative stress